Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk

International Journal of Cardiology

Volumn 163, Issue 1, 2013, Pages 5-18

  Bassand, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Acute coronary syndromes; ADP; Bleeding; PAR 1; Thrombin; Thromboxane A 2

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; ATOPAXAR; CANGRELOR; CLOPIDOGREL; DABIGATRAN ETEXILATE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; REVIPARIN; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICAGRELOR; TIROFIBAN; UNINDEXED DRUG; VORAPAXAR; WARFARIN; XIMELAGATRAN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPETITIVE INHIBITION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DYSPNEA; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTIMAL DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CLINICAL EVALUATION; HEMOSTASIS; ISCHEMIA; MORBIDITY; RISK ASSESSMENT; RISK REDUCTION; THROMBOEMBOLISM; THROMBUS; VASCULAR ACCESS;

ACUTE CORONARY SYNDROME; ANIMALS; BLOOD COAGULATION; CLINICAL TRIALS, PHASE III AS TOPIC; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; RISK FACTORS;

EID: 84873080245     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.104     Document Type: Review

References (98)

1. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 e1 e157
2. J.P. Bassand, C.W. Hamm, and D. Ardissino Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
3. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
4. F. Van de Werf, J. Bax, and A. Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
5. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
6. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin Ann Neurol 42 1997 857 865
7. T.D. Kinnaird, E. Stabile, and G.S. Mintz Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935
8. M. Moscucci, K.A. Fox, and C.P. Cannon Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1815 1823
9. S.V. Rao, K. O'Grady, and K.S. Pieper Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206
10. G. Davi, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
11. J.I. Weitz, J. Hirsh, M.M. Samama, and American College of Chest Physicians New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 234S 256S
12. S. Offermanns Activation of platelet function through G protein-coupled receptors Circ Res 99 2006 1293 1304
13. D. Varga-Szabo, I. Pleines, and B. Nieswandt Cell adhesion mechanisms in platelets Arterioscler Thromb Vasc Biol 28 2008 403 412
14. K.G. Mann Thrombin formation Chest 124 2003 4S 10S
15. T.A. Meadows, and D.L. Bhatt Clinical aspects of platelet inhibitors and thrombus formation Circ Res 100 2007 1261 1275
16. K. Jurk, and B.E. Kehrel Platelets: physiology and biochemistry Semin Thromb Hemost 31 2005 381 392
17. A. Zarbock, R.K. Polanowska-Grabowska, and K. Ley Platelet-neutrophil- interactions: linking hemostasis and inflammation Blood Rev 21 2007 99 111
18. K.E. Brummel, S.G. Paradis, S. Butenas, and K.G. Mann Thrombin functions during tissue factor-induced blood coagulation Blood 100 2002 148 152
19. S.R. Coughlin Protease-activated receptors in hemostasis, thrombosis and vascular biology J Thromb Haemost 3 2005 1800 1814
20. T.T. Suh, K. Holmback, and N.J. Jensen Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice Genes Dev 9 1995 2020 2033
21. C.K. Derian, B.P. Damiano, and M.F. Addo Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates J Pharmacol Exp Ther 304 2003 855 861
22. Y. Kato, Y. Kita, and Y. Hirasawa-Taniyama Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig Eur J Pharmacol 473 2003 163 169
23. M.R. Lassen, and V. Laux Emergence of new oral antithrombotics: a critical appraisal of their clinical potential Vasc Health Risk Manag 4 2008 1373 1386
24. M. Di Nisio, S. Middeldorp, and H.R. Buller Direct thrombin inhibitors N Engl J Med 353 2005 1028 1040
25. N.C. Raju, J.W. Eikelboom, and J. Hirsh Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future Nat Clin Pract Cardiovasc Med 5 2008 766 780
26. J. Hirsh, M. O'Donnell, and J.W. Eikelboom Beyond unfractionated heparin and warfarin: current and future advances Circulation 116 2007 552 560
27. H. Bounameaux The novel anticoagulants: entering a new era Swiss Med Wkly 139 2009 60 64
28. R.L. Sacco, R. Adams, and G. Albers Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline Circulation 113 2006 e409 e449
29. R.A. Harrington, R.C. Becker, and C.P. Cannon Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 670S 707S
30. S. Dhillon Argatroban: a review of its use in the management of heparin-induced thrombocytopenia Am J Cardiovasc Drugs 9 2009 261 282
31. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf RE-LY Steering Committee Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
32. G. Agnelli, A. Gallus, and S.Z. Goldhaber Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study Circulation 116 2007 180 187
33. A.G. Turpie Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases Arterioscler Thromb Vasc Biol 27 2007 1238 1247
34. J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, and S. Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
35. S. Fuchs, R. Kornowski, and I. Teplitsky Major bleeding complicating contemporary primary percutaneous coronary interventions-incidence, predictors, and prognostic implications Cardiovasc Revasc Med 10 2009 88 93
36. D.P. Chew, Z. Huang, and K.S. Pieper Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy Am Heart J 155 2008 239 244
37. T.Y. Wang, L. Xiao, and K.P. Alexander Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding Circulation 118 2008 2139 2145
38. F.A. Spencer, M. Moscucci, and C.B. Granger Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 116 2007 2793 2801
39. J.P. Bassand, R. Afzal, and J. Eikelboom Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes Eur Heart J 31 2010 50 58
40. S.V. Rao, J.G. Jollis, and R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562
41. S. Subherwal, R.G. Bach, and A.Y. Chen Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Circulation 119 2009 1873 1882
42. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
43. S.G. Goodman, V. Menon, C.P. Cannon, G. Steg, E.M. Ohman, and R.A. Harrington Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 708S 775S
44. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
45. Z.M. Chen, L.X. Jiang, and Y.P. Chen COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
46. M.S. Sabatine, C.P. Cannon, and C.M. Gibson CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
47. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
48. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA 294 2005 1224 1232
49. S.R. Steinhubl, P.B. Berger, and J.T. Mann III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
50. S. Yusuf, S.R. Mehta, and F. Zhao Early and late effects of clopidogrel in patients with acute coronary syndromes Circulation 107 2003 966 972
51. D.L. Bhatt, K.A. Fox, and W. Hacke Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
52. D.L. Bhatt, M.D. Flather, and W. Hacke Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol 49 2007 1982 1988
53. E. Boersma, R.A. Harrington, and D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
54. R.P. Giugliano, J.A. White, and C. Bode Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
55. G.W. Stone, M.E. Bertrand, and J.W. Moses Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial JAMA 297 2007 591 602
56. C. Geeganage, R. Wilcox, and P.M. Bath Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis BMC Med 8 2010 36
57. F. Ottani, L. La Vecchia, M. De Vita, O. Catapano, F. Tarantino, and M. Galvani Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention Am J Cardiol 106 2010 167 174 e1.
58. U. Zeymer, A. Margenet, and M. Haude Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial J Am Coll Cardiol 56 2010 463 469
59. S.R. Mehta, J.P. Bassand, and S. Chrolavicius Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
60. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1203 1205
61. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
62. S.D. Wiviott, E. Braunwald, and D.J. Angiolillo Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 118 2008 1626 1636
63. G. Montalescot, S.D. Wiviott, and E. Braunwald TRITON-TIMI 38 Investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
64. S.D. Wiviott, E. Braunwald, and C.H. McCabe TRITON-TIMI 38 Investigators Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
65. S. Husted, H. Emanuelsson, S. Heptinstall, P.M. Sandset, M. Wickens, and G. Peters Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
66. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
67. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
68. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
69. L.K. Jennings Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis Thromb Haemost 102 2009 248 257
70. M. Kogushi, H. Kobayashi, and T. Matsuoka Anti-thrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs Circulation 108 Suppl IV 2003 IV-280 Abstract 1327.
71. V.L. Serebruany, M. Kogushi, D. Dastros-Pitei, M. Flather, and D.L. Bhatt The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb Haemost 102 2009 111 119
72. S. Goto, H. Ogawa, M. Takeuchi, M.D. Flather, and D.L. Bhatt Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur Heart J 31 2010 2601 2613
73. S. Chackalamannil, Y. Wang, and W.J. Greenlee Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J Med Chem 51 2008 3061 3064
74. R.C. Becker, D.J. Moliterno, and L.K. Jennings Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
75. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale Am Heart J 158 2009 327 334 e4.
76. D.A. Morrow, B.M. Scirica, and K.A. Fox Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial Am Heart J 158 2009 335 341 e3
77. F. Van de Werf Inhibitors of the platelet thrombin receptor: will they live up to their promises? Circulation 123 2011 1833 1835
78. A. Oler, M.A. Whooley, J. Oler, and D. Grady Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis JAMA 276 1996 811 815
79. J.W. Eikelboom, D.J. Quinlan, S.R. Mehta, A.G. Turpie, I.B. Menown, and S. Yusuf Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials Circulation 112 2005 3855 3867
80. E.M. Antman, D.A. Morrow, and C.H. McCabe ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 2006 1477 1488
81. S. Yusuf, S.R. Mehta, and C. Xie Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation JAMA 293 2005 427 435
82. S.A. Murphy, C.M. Gibson, and D.A. Morrow Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis Eur Heart J 28 2007 2077 2086
83. J.J. Ferguson, R.M. Califf, and E.M. Antman Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
84. S. Yusuf, S.R. Mehta, and S. Chrolavicius Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
85. S.R. Mehta, C.B. Granger, and J.W. Eikelboom Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial J Am Coll Cardiol 50 2007 1742 1751
86. S. Yusuf, S.R. Mehta, and S. Chrolavicius Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 2006 1519 1530
87. J.A. Anderson, J. Hirsh, and S. Yusuf Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial J Thromb Haemost 8 2010 243 249
88. P.G. Steg, S.S. Jolly, and S.R. Mehta Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial JAMA 304 2010 1339 1349
89. G.W. Stone, B.T. McLaurin, and D.A. Cox Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
90. G.W. Stone, B. Witzenbichler, and G. Guagliumi HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
91. J.L. Mega, E. Braunwald, and S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
92. J.H. Alexander, R.C. Becker, and D.L. Bhatt Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
93. J. Oldgren, A. Budaj, and C.B. Granger Randomized dagibatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel American Heart Association (AHA) 2009 Congress November 14-18, 2009. Orlando, FL 2009
94. J. Oldgren, A. Budaj, and C.B. Granger Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 10.1093/eurheartj/ehr113 first published online May 7, 2011
95. M.B. Rothberg, C. Celestin, L.D. Fiore, E. Lawler, and J.R. Cook Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit Ann Intern Med 143 2005 241 250
96. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
97. C.M. Gibson, J.L. Mega, and P. Burton Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 2011 815 821 e6.
98. H.D. White, N.S. Kleiman, and K.W. Mahaffey Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial Am Heart J 152 2006 1042 1050